Skip to main content
. 2016 Aug 3;6:30896. doi: 10.1038/srep30896

Figure 1. Rbfox2 undergoes changes in HLHS patient hearts.

Figure 1

(a) The effect of de novo nonsense mutation identified in HLHS patients on Rbfox2 protein. (b) Quantification of mRNA levels of Rbfox2 in control and HLHS patient hearts determined by qRT-PCR after normalizing to GADPH mRNA levels. (n ≥ 3), ns: not significant. (c) WB analysis of heart protein lysates from controls or HLHS patients using anti-Rbfox2, anti-Rbfox1 and anti-PKCalpha/beta antibodies. Ponceau S staining of the membrane was used to monitor protein loading. (d) Analysis of Rbfox2 protein in control or HLHS patient hearts using two-dimensional (2D) gel electrophoresis followed by WB using anti-Rbfox2 antibody. Four black arrows indicate Rbfox2 isoforms in HLHS hearts. (e) DN Rbfox2 expression in control vs HLHS patient hearts determined by exon 6 exclusion using qRT-PCR. (n ≥ 3), ns: not significant.